Salubris Biotherapeutics, Inc., a Gaithersburg, MD-based clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, received $32m in financing.
China-based Shenzhen Salubris Pharmaceuticals Co., made the investment.
The company intends to use the funds to used to advance the current pipeline, including continuation of an ongoing Phase 1b clinical trial and initiation of two additional Phase 1b clinical trials in 2022, and to further expand the pipeline through R&D.
Led by Sam Murphy, Chief Executive Officer, SalubrisBio has built a drug discovery and development platform to address significant unmet medical needs in cardiovascular diseases, cancer and neurodegenerative diseases. The company has multiple assets in clinical/preclinical development and additional programs at the discovery stage. The company’s lead asset, JK07, is an antibody-based NRG-1 fusion protein currently in Phase 1 trials to assess safety and tolerability and to explore activity in subjects with heart failure with reduced ejection fraction [HFrEF]. JK07 is the first bi-specific antibody globally to enter a clinical trial in a cardiovascular indication.
FinSMEs
07/03/2022